New pneumonia vaccine tested in babies and adults

This early-stage study tested a new vaccine designed to protect against 13 types of pneumococcal bacteria that can cause pneumonia and other serious infections. Researchers enrolled 310 healthy participants ranging from infants as young as 6 weeks to adults up to 49 years old to compare the new vaccine's safety and immune response against two existing pneumonia vaccines. The main goal was to see how often side effects occurred and measure how well the vaccine stimulated protective antibodies in different age groups.